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Although considerable progress has been made in thediagnosis and treatment of non-small cell lung cancer
(NSCLC) in recent years, this disease is still associated with
a dismal prognosis. Some improvements have been reported
recently after the implementation of third-generation drugs
into the clinic. Realistically, we have probably reached a
plateau in terms of clinical outcomes with the ways in which
we are currently administering cytotoxic chemotherapy. Fur-
ther steps could be the implementation of molecularly tar-
geted therapies and pharmacogenomics into the therapeutic
armamentarium. Pharmacogenomics is the branch of pharma-
ceutics that deals with the influence of genetic variation on
drug response in patients by correlating gene expression or
single-nucleotide polymorphisms with a drug’s efficacy or
toxicity. In this way, pharmacogenomics aims to develop
rational means of optimizing drug therapy with respect to the
patient’s genotype, to ensure maximal efficacy with minimal
adverse effects. Such approaches suggest the advent of “per-
sonalized medicine,” in which drugs and drug combinations
are optimized for each individual’s unique genetic makeup.
Pharmacogenomics, the whole genome application of
pharmacogenetics that examines the single gene interactions
with drugs, holds the promise that drugs might one day be
tailored to the individual and adapted to each person’s genetic
makeup. Environment, diet, age, lifestyle, and state of health
can all influence a person’s response to medicines, but un-
derstanding an individual’s genetic makeup is thought to be
the key to creating personalized drugs with greater efficacy
and safety.
What Are the Anticipated Benefits of Pharmacog-
enomics?
Pharmaceutical companies will be able to create drugs
based on the proteins, enzymes, and RNA molecules associ-
ated with genes and diseases. This will facilitate drug discov-
ery and allow drug makers to produce a therapy more targeted
to specific diseases. This accuracy will not only maximize
therapeutic effects, but also decrease damage to nearby
healthy cells. Instead of the standard trial-and-error method
of matching patients with the right drugs, physicians will be
able to analyze a patient’s genetic profile and prescribe the
best available drug therapy from the very beginning. This will
not only take the guesswork out of finding the right drug, but
also speed up recovery time and increase safety as the
likelihood of adverse reactions is eliminated.
Pharmacogenomics has the potential to dramatically
reduce the estimated 100,000 deaths and 2 million hospital-
izations that occur each year in the United States as the result
of adverse drug response. Current methods of dosing based
on weight and age will be replaced with dosages based on a
person’s genetics, which will maximize the value of the
therapy and decrease the chance of overdose.
The decrease in the number of adverse drug reactions,
the number of failed drug trials, the time it takes to get a drug
approved, the length of time patients receive medication, the
number of medications patients must take to find an effective
therapy, the effects of a disease on the body (through early
detection), and an increase in the range of possible drug
targets will promote a net decrease in the cost of health care.
GENETIC POLYMORPHISMS AND
LUNG CANCER
Although the genome of individuals is 99.9% identical,
that small 0.1% difference predicts as many as 3 million
polymorphisms, which have almost no effects. However, many
of them are able to influence protein expression and function,
resulting in phenotypes that affect disease or drug response.
The genomic approach may lead us to a new world of
gene-based medicine, although it is unlikely to materialize for
at least another decade. Considering the genetic variation, we
can theoretically predict how a patient will respond to a single
drug, but the expectations are more relevant, and they include
the optimization of drug dosing, reduction of adverse events,
improvement of clinical outcomes, and reduction of costs.
Polymorphisms are particularly attractive because they
are easy to investigate using any source of DNA, including
peripheral blood. For this reason, it is not surprising that the
birth of pharmacogenomic research was linked to the identi-
fication of specific gene polymorphisms involved in altered
drug metabolism or transport; this information could be used
to identify groups of patients with a high risk of developing
severe drug toxicity and/or poor anticancer response with
specific cytotoxic drugs, leading to the principle of individ-
ualized chemotherapy.
The concept of specific genetic markers that can predict
response to each of the main cytotoxic drugs is closely linked
to DNA damage and repair. Radiation therapy and alkylating
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agents, including cisplatin, show the same indiscriminate
mechanism of cell damage. Each gray of ionizing radiation
causes thousands of single-strand DNA breaks in each cell,
cross-links in DNA and with DNA-associated proteins, and
30 to 40 double-strand DNA breaks. Most of this damage is
repaired. One of the earliest events after DNA strand break-
age by radiation is the poly(ADP-ribosylation) of surrounding
proteins by poly(ADP-ribose) polymerase (PARP). PARP
binds to single-strand and double-strand breaks to catalyze
the transfer of successive units of ADP-ribose from NAD1
covalently with itself and with other nuclear acceptor
proteins, including p53. PARP-deficient cells are more
radiosensitive and exhibit genomic instability, and PARP
cycling may be important in apoptosis, DNA replication,
and DNA repair.2
Several studies have documented that a polymorphism
in the DNA base excision repair gene XRCC1 (Arg399Gln)
is associated with reduced DNA repair capacity as assessed
by the persistence of DNA adducts. This polymorphism is
associated with the incidence of several common cancers:
head and neck, breast, lung, bladder, stomach, and colorectal.
XRCC1 directly participates in both base excision and single-
strand break repair. The arg399gln polymorphism occurs at a
conserved residue in the PARP-binding domain of XRCC1
and may alter the efficiency of repair processes.3 Hence, the
XRCC1 arg399gln polymorphism could be a good sensor of
response to radiation therapy and cisplatin, although few
studies have examined the real value of this marker in the
clinical setting.
We have recently genotyped 203 patients with non-
small cell lung cancer (NSCLC) and 45 patients with small
cell lung cancer (SCLC) for the XPD Lys751Gln and XRCC1
Arg399Gln single nucleotide polymorphisms and correlated
the results with clinical outcome. Most of the patients (81%)
received platinum-based chemotherapy. The patients’ geno-
type frequencies did not significantly differ from controls,
and both groups were in Hardy-Weinberg equilibrium for the
two polymorphisms. The XRCC1399 variant Gln/Gln geno-
type was associated with higher median survival time (80 vs
54.6 weeks for the Arg/Gln heterozygous and 55.6 weeks for
the wild-type Arg/Arg genotype; p  0.09). At multivariable
analysis adjusted for histology, stage of disease, performance
status, age, and gender, the Gln/Gln genotype was associated
with a better survival of borderline significance in the sub-
group of patients treated with cisplatin (HR 0.55, 95%CI
0.30–1.00); this association became significant for those with
grade III or IV clinical toxicity (HR  0.46, 95%CI 
0.22–0.98). No association between XPD Lys751Gln geno-
type and clinical outcome was found.
This prospective investigation provides suggestive ev-
idence of a favorable effect of the XRCC1399 Gln/Gln
genotype on survival for platinum-treated NSCLC and, for
the first time, for SCLC.4
GENETIC PROFILING OF LUNG CANCER
Unfortunately, in NSCLC, as in most malignancies,
there are polygenic variations: the influence of environment,
lifestyle (e.g., smoking habits), and health status play a
relevant role in the pathogenesis, prognosis, and response to
treatment. These are good reasons to believe that the evalu-
ation of a single gene will not be sufficient, but it is a good
starting point.
Cisplatin remains a milestone in the treatment of
NSCLC, and its activity is mainly the result of the formation
of DNA adducts, the removal of which is performed by the
nucleotide excision repair pathway (NER). Cisplatin resis-
tance is also related to an increased removal of these adducts;
therefore, NER plays a key role in this event.
The NER pathway consists of several steps: damage
recognition, dual incision/excision, repair synthesis, and li-
gation. Approximately 30 proteins participate in this repair
process; in particular, excision repair cross-complementing 1
(ERCC1) has a crucial role in the incision process, which is
the rate-limiting step of the pathway. ERCC1 is a 15-kb
repair gene located on human chromosome 19. ERCC1 forms
a heterodimer with XPF, and the ERCC1/XPF complex is
responsible for the incision cleaving the damaged strand at
the phosphodiester bonds between 22 and 24 nucleotides 5= to
the lesion.
ERCC1 defective cells have the most severe DNA
repair-deficient phenotype. High ERCC1 mRNA levels are a
good prognostic factor after surgery for early-stage NSCLC
and predict poor outcome from platinum-based therapies in
different cancers.5
In a pivotal study, the role of ERCC1 expression in
patients with NSCLC treated with gemcitabine/cisplatin was
investigated in tumor samples by using quantitative polymer-
ase chain reaction. The median ERCC1 expression in the 56
patients analyzed was 6.7 relative to the expression of the
control -actin. Patients with ERCC1 expression greater than
6.7 had a median survival of 5 months, in contrast with those
with lower levels, for whom the median survival was 15
months. This difference was statistically significant, and,
more importantly, ERCC1 levels were as an independent
predictive variable in a Cox multivariable analysis.
The same type of phenomenon was observed in our
laboratory experience, in which we found an inverse relation-
ship between ERCC1 expression level in the tumor and
median survival in patients with advanced NSCLC; the pre-
dictive information provided by ERCC1 was also maintained
at multivariate analysis (p  0.0026).
Recently, the results of a prospective clinical study in
which patients with advanced NSCLC were randomized to
receive standard chemotherapy (cisplatin/docetaxel) or cus-
tomized treatment according to ERCC1 intratumoral levels
(low ERCC1 level: cisplatin/docetaxel, high ERCC1 levels:
gemcitabine/ docetaxel) have been reported. More than 400
patients were included, and the main objective of the study
(response rate) was reached: the response rate for patients
with low ERCC1 expression (56.6%) was shown to be sig-
nificantly higher than that for the patients in the control arm
(40.4%; p  0.02).6
In the adjuvant setting, a retrospective study performed
by the IALT investigators assessed the role of ERCC1 ex-
pression as evaluated by immunohistochemical analysis.
They found that the benefit of adjuvant chemotherapy was
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confined to those tumors that were ERCC1 negative, and a
paradoxical effect was observed in ERCC1-positive tumors.7
BCRA1 is a part of the DNA repair pathway and is
considered a molecular marker of response to a range of
DNA-damaging and antimicrotubule agents. In some types of
cancers, including NSCLC, the BRCA1 function is abro-
gated, which increases sensitivity to cisplatin and resistance
to antimicrotubule drugs.8 Rosell et al. reported a correlation
between BCRA1 and ERCC1 mRNA expression and a role of
BCRA1 mRNA level in predicting outcomes for patients with
locally advanced NSCLC treated with neoadjuvant gemcit-
abine plus cisplatin followed by surgery.9
The chromosomal aberrations in cancer could consist of
deletion, translocation, and insertion. The technique most
frequently used to assess these aberrations is loss-of-het-
erozygosity (LOH) analysis. Many chromosomal regions
with frequent LOH were detected in lung cancer, leading to
the identification of tumor-suppressor genes with potential in-
volvement in the development and progression of this disease.
For instance, a part of chromosome 11 was mapped and se-
quenced, and the corresponding tumor suppressor gene named
ribonucleotide reductase subunit M1 (RRM1) was identified
within this area. Overexpression of RRM1 results in a more
benign phenotype: for patients with resectable NSCLC, survival
was better in cases of high RRM1 expression.10
Ribonucleotide reductase has a key role in DNA syn-
thesis and repair, and RRM1 is the most likely intracellular
target for gemcitabine. Davidson et al. identified increased
expression of RRM1 as the major determinant of gemcitabine
resistance.11
Two retrospective studies identified RRM1 as a predic-
tive marker of survival for patients with advanced NSCLC
treated with cisplatin and gemcitabine. In our experience,
when patients with advanced NSCLC treated with cisplatin/
gemcitabine were analyzed for RRM1 expression, we found
an inverse correlation with survival at univariate analysis
(p  0.00390) and a close correlation between ERCC1 and
RRM1 levels.12
As previously observed for ERCC1, there is an appar-
ently contradictory role of these markers in early versus
advanced disease. High levels of ERCC1 and RRM1 predict
better survival in early disease but a worse one in advanced
NSCLC treated with cisplatin-based chemotherapy. Actually,
this is simply the expression of a different prognostic and
predictive role of these two genetic markers in NSCLC.
An ongoing study performed at the Moffitt Cancer
Center in Tampa, Florida, is selecting chemotherapy treat-
ment on the basis of a differential expression of RRM1 and
ERCC1 in fresh tumor specimens.
Thymidylate synthase (TS) is an enzyme with an im-
portant role in DNA biosynthesis that is the target enzyme for
many antimetabolite agents, including pemetrexed. In many
studies, an adverse effect of higher TS levels on prognosis
has been documented in different types of human cancers.
For patients with colorectal cancer, it was reported that low
microsatellite instability, the genotype 2R/2R of the 5=-
untranslated region-enhancer region of the TS gene, and
lower intratumoral expression levels were associated with a
good response to chemotherapy.13 TS protein expression
correlates significantly with higher proliferative activity of
NSCLC cells and with poor prognosis. We designed a study
to investigate the detection of TS gene activity and protein
expression in patients with chemotherapy-naive NSCLC. We
included 56 patients from stage I to IIIA, most with adeno-
carcinoma histology. The quantification of mRNA from for-
malin-fixed, paraffin-embedded specimens was performed in
real-time polymerase chain reaction, and the median expres-
sion level for adenocarcinoma was 1.16, whereas the median
expression level was 2.17 for squamous cell carcinoma (p 
0.0001) (Figure 1). Comparable results were documented in
the IHC analysis. This could explain the unique data regard-
ing UFT activity in the adjuvant setting, as previously re-
ported by Japanese investigators: 84% of patients included in
the UFT Japanese meta-analysis had a diagnosis of adeno-
carcinoma, and no benefit was reported for patients with
squamous carcinoma. We also found a strong correlation
between TS mRNA and protein levels. The analysis of TS
transcript regulation in snap-frozen specimens by polymerase
chain reaction showed that TS expression levels in tumors
were considerably higher than levels in normal tissues.14
CONCLUSION
Pharmacogenomics may represent a major step forward
in improving the outcomes of cytotoxic chemotherapy in
many solid tumors, but there is urgent need for the prospec-
tive validation of the experimental hypothesis. In addition to
the benefits, a number of potential barriers to the implemen-
tation should be recognized. First, the correlation is not
always 100% because of polygenic and environmental influ-
ences. Second, the correlation requires biological plausibility,
which may be possible with a haplotype but not with a
specific mutation. Finally, the concept requires clinical vali-
FIGURE 1. Thymidylate synthase mRNA levels in adenocar-
cinoma compared with squamous cell carcinoma. The hori-
zontal lines in the boxes represent median values; upper and
lower bars represent the distance of the 10th and 90th per-
centile from the median. p  0.0001.
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dation through specifically designed clinical studies, and the
development of a specific test may not be a sufficient eco-
nomic incentive. In fact, patents can be appealing from a
financial point of view but at the same time be a cause of
stagnation.
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